5 Stocks to Buy According to Peter Simmie’s Bristol Gate Capital Partners

In this article, we discuss 5 stocks to buy according to Peter Simmie’s Bristol Gate Capital Partners. If you want to read a detailed analysis of Simmie’s investment philosophy and current portfolio allocation strategies, go directly to 10 Stocks to Buy According to Peter Simmie’s Bristol Gate Capital Partners.

5. Thermo Fisher Scientific Inc. (NYSE:TMO)

Bristol Gate Capital Partners’ Stake Value: $90,926,000
Percentage of Bristol Gate Capital Partners’ 13F Portfolio: 5.14%
Number of Hedge Fund Holders: 93

Thermo Fisher Scientific Inc. (NYSE:TMO) provides software, services, reagents, equipment, and analytical instruments for research, analysis, discovery, and diagnostics. Thermo Fisher Scientific Inc. (NYSE:TMO)’s largest Q2 shareholder is Fisher Asset Management, with a $1.27 billion stake which saw a 4% increase over the previous quarter.

On August 24, Credit Suisse analyst Dan Leonard initiated coverage of Thermo Fisher Scientific Inc. (NYSE:TMO), rating the stock as ‘Neutral’ with a $675 price target. The analyst was optimistic about the company’s better business mix and share gain prospects.

Thermo Fisher Scientific Inc. (NYSE:TMO) recently experienced a decrease in hedge fund interest. Thermo Fisher Scientific Inc. (NYSE:TMO) was in 93 hedge fund portfolios at the end of the second quarter of 2022. There were 101 hedge funds in our database with Thermo Fisher Scientific Inc. (NYSE:TMO) holdings at the end of the previous quarter.

Bristol Gate Capital Partners sold 2,660 shares of Thermo Fisher Scientific Inc. (NYSE:TMO), reducing its remaining stake by about 2%. At the end of the second quarter, the hedge fund still held 167,363 shares of Thermo Fisher Scientific Inc. (NYSE:TMO), worth about $90.93 million, representing 5.14% of its portfolio.

Investment firm Stewart Asset Management explained its insights for Thermo Fisher Scientific Inc. (NYSE:TMO) in its Q2 2022 investor letter, stating:

“Recently we initiated two new investments. One in Thermo Fischer Scientific (NYSE:TMO), a supplier to the life sciences industry. We have followed the company for many years and the recent downturn in share price gave us a good entry price at which to invest. Thermo has had strong earnings growth for many years and is led by a superb team. The company’s recent acquisitions make it a full-service supplier to the biopharma and biotech industries.”